{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:00:14Z","timestamp":1774353614323,"version":"3.50.1"},"reference-count":36,"publisher":"Journal of Biomedical Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Biomed Res"],"published-print":{"date-parts":[[2026]]},"DOI":"10.7555\/jbr.39.20250197","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:33:11Z","timestamp":1761618791000},"page":"185","source":"Crossref","is-referenced-by-count":2,"title":["NS3 epitope-decorated nanoparticles produced in bacteria trigger potent T cell immunity against hepatitis C virus"],"prefix":"10.7555","volume":"40","author":[{"given":"Victor V.","family":"Kuprianov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyudmila I.","family":"Nikolaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya D.","family":"Stuchinskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0410nna A.","family":"Zykova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai V.","family":"Ravin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4380","reference":[{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.1","doi-asserted-by":"publisher","unstructured":"Tu T, B\u00fchler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer[J]. <i>Biol Chem<\/i>, 2017, 398(8): 817\u2013837.","DOI":"10.1515\/hsz-2017-0118"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.2","doi-asserted-by":"publisher","unstructured":"Holz L, Rehermann B. T cell responses in hepatitis C virus infection: Historical overview and goals for future research[J]. <i>Antivir Res<\/i>, 2015, 114: 96\u2013105.","DOI":"10.1016\/j.antiviral.2014.11.009"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.3","doi-asserted-by":"publisher","unstructured":"Spengler U. Direct antiviral agents (DAAs)\u2014a new age in the treatment of hepatitis C virus infection[J]. <i>Pharmacol Ther<\/i>, 2018, 183: 118\u2013126.","DOI":"10.1016\/j.pharmthera.2017.10.009"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.4","doi-asserted-by":"publisher","unstructured":"Masavuli MG, Wijesundara DK, Torresi J, et al. Preclinical development and production of virus-like particles as vaccine candidates for hepatitis C[J]. <i>Front Microbiol<\/i>, 2017, 8: 2413.","DOI":"10.3389\/fmicb.2017.02413"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.5","doi-asserted-by":"publisher","unstructured":"Raman S, Machaidze G, Lustig A, et al. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles[J]. <i>Nanomedicine<\/i>, 2006, 2(2): 95\u2013102.","DOI":"10.1016\/j.nano.2006.04.007"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.6","doi-asserted-by":"publisher","unstructured":"Babapoor S, Neef T, Mittelholzer C, et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection[J]. <i>Influenza Res Treat<\/i>, 2011, 2011: 126794.","DOI":"10.1155\/2011\/126794"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.7","doi-asserted-by":"publisher","unstructured":"Herring BL, Tsui R, Peddada L, et al. Wide range of quasispecies diversity during primary hepatitis C virus infection[J]. <i>J Virol<\/i>, 2005, 79(7): 4340\u20134346.","DOI":"10.1128\/JVI.79.7.4340-4346.2005"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.8","doi-asserted-by":"publisher","unstructured":"Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution[J]. <i>J Virol<\/i>, 1992, 66(5): 3225\u20133229.","DOI":"10.1128\/jvi.66.5.3225-3229.1992"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.9","doi-asserted-by":"publisher","unstructured":"Adugna A. Therapeutic strategies and promising vaccine for hepatitis C virus infection[J]. <i>Immun Inflamm Dis<\/i>, 2023, 11(8): e977.","DOI":"10.1002\/iid3.977"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.10","doi-asserted-by":"publisher","unstructured":"Lechner F, Wong DKH, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus[J]. <i>J Exp Med<\/i>, 2000, 191(9): 1499\u20131512.","DOI":"10.1084\/jem.191.9.1499"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.11","doi-asserted-by":"publisher","unstructured":"Shoukry NH, Grakoui A, Houghton M, et al. Memory CD8<sup>+<\/sup> T cells are required for protection from persistent hepatitis C virus infection[J]. <i>J Exp Med<\/i>, 2003, 197(12): 1645\u20131655.","DOI":"10.1084\/jem.20030239"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.12","doi-asserted-by":"publisher","unstructured":"Thimme R, Oldach D, Chang K, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection[J]. <i>J Exp Med<\/i>, 2001, 194(10): 1395\u20131406.","DOI":"10.1084\/jem.194.10.1395"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.13","doi-asserted-by":"publisher","unstructured":"Wedemeyer H, He X, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8<sup>+<\/sup> T cells in chronic hepatitis C virus infection[J]. <i>J Immunol<\/i>, 2002, 169(6): 3447\u20133458.","DOI":"10.4049\/jimmunol.169.6.3447"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.14","doi-asserted-by":"publisher","unstructured":"Boettler T, Spangenberg HC, Neumann-Haefelin C, et al. T cells with a CD4<sup>+<\/sup>CD25<sup>+<\/sup> regulatory phenotype suppress <i>in vitro<\/i> proliferation of virus-specific CD8<sup>+<\/sup> T cells during chronic hepatitis C virus infection[J]. <i>J Virol<\/i>, 2005, 79(12): 7860\u20137867.","DOI":"10.1128\/JVI.79.12.7860-7867.2005"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.15","doi-asserted-by":"publisher","unstructured":"Spangenberg HC, Viazov S, Kersting N, et al. Intrahepatic CD8<sup>+<\/sup> T-cell failure during chronic hepatitis C virus infection[J]. <i>Hepatology<\/i>, 2005, 42(4): 828\u2013837.","DOI":"10.1002\/hep.20856"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.16","doi-asserted-by":"publisher","unstructured":"Lauer GM, Barnes E, Lucas M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection[J]. <i>Gastroenterology<\/i>, 2004, 127(3): 924\u2013936.","DOI":"10.1053\/j.gastro.2004.06.015"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.17","doi-asserted-by":"publisher","unstructured":"Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C[J]. <i>Nat Med<\/i>, 2000, 6(5): 578\u2013582.","DOI":"10.1038\/75063"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.18","doi-asserted-by":"publisher","unstructured":"Ward S, Lauer G, Isba R, et al. Cellular immune responses against hepatitis C virus: The evidence base 2002[J]. <i>Clin Exp Immunol<\/i>, 2002, 128(2): 195\u2013203.","DOI":"10.1046\/j.1365-2249.2002.01840.x"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.19","doi-asserted-by":"publisher","unstructured":"Lauer GM, Lucas M, Timm J, et al. Full-breadth analysis of CD8<sup>+<\/sup> T-cell responses in acute hepatitis C virus infection and early therapy[J]. <i>J Virol<\/i>, 2005, 79(20): 12979\u201312988.","DOI":"10.1128\/JVI.79.20.12979-12988.2005"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.20","doi-asserted-by":"publisher","unstructured":"Manns MP, Berg T, Wedemeyer H, et al. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non-responder patients[J]. <i>Hepatology<\/i>, 2004, 40(S1): 251A.","DOI":"10.1053\/j.gastro.2008.02.058"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.21","doi-asserted-by":"publisher","unstructured":"Firbas C, Jilma B, Tauber E, et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects[J]. <i>Vaccine<\/i>, 2006, 24(20): 4343\u20134353.","DOI":"10.1016\/j.vaccine.2006.03.009"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.22","doi-asserted-by":"publisher","unstructured":"Schlaphoff V, Klade CS, Jilma B, et al. Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients[J]. <i>Vaccine<\/i>, 2007, 25(37-38): 6793\u20136806.","DOI":"10.1016\/j.vaccine.2007.06.026"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.23","doi-asserted-by":"publisher","unstructured":"Hart DNJ. Dendritic cells: Unique leukocyte populations which control the primary immune response[J]. <i>Blood<\/i>, 1997, 90(9): 3245\u20133287.","DOI":"10.1182\/blood.V90.9.3245"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.24","doi-asserted-by":"publisher","unstructured":"Gluckman JC, Canque B, Rosenzwajg M. Dendritic cells: A complex simplicity[J]. <i>Transplantation<\/i>, 2002, 73(S1): S3\u2013S6.","DOI":"10.1097\/00007890-200201151-00004"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.25","doi-asserted-by":"publisher","unstructured":"Gowans EJ, Roberts S, Jones K, et al. A phase \u2160 clinical trial of dendritic cell immunotherapy in HCV-infected individuals[J]. <i>J Hepatol<\/i>, 2010, 53(4): 599\u2013607.","DOI":"10.1016\/j.jhep.2010.05.007"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.26","doi-asserted-by":"publisher","unstructured":"Kuzushita N, Gregory SH, Monti NA, et al. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens[J]. <i>Gastroenterology<\/i>, 2006, 130(2): 453\u2013464.","DOI":"10.1053\/j.gastro.2005.10.048"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.27","doi-asserted-by":"publisher","unstructured":"Alexander J, del Guercio MF, Maewal A, et al. Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses[J]. <i>J Immunol<\/i>, 2000, 164(3): 1625\u20131633.","DOI":"10.4049\/jimmunol.164.3.1625"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.28","doi-asserted-by":"publisher","unstructured":"Huang XJ, L\u00fc X, Lei YF, et al. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice[J]. <i>J Virol Methods<\/i>, 2013, 189(1): 47\u201352.","DOI":"10.1016\/j.jviromet.2013.01.003"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.29","doi-asserted-by":"publisher","unstructured":"Arai R, Ueda H, Kitayama A, et al. Design of the linkers which effectively separate domains of a bifunctional fusion protein[J]. <i>Protein Eng<\/i>, 2001, 14(8): 529\u2013532.","DOI":"10.1093\/protein\/14.8.529"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.30","unstructured":"MPI Bioinformatics Toolkit. PCOILS[EB\/OL]. [2025-05-01]. https:\/\/toolkit.tuebingen.mpg.de\/tools\/pcoils."},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.31","doi-asserted-by":"publisher","unstructured":"Gomes LC, Mergulh\u00e3o FJ. Effects of antibiotic concentration and nutrient medium composition on <i>Escherichia coli<\/i> biofilm formation and green fluorescent protein expression[J]. <i>FEMS Microbiol Lett<\/i>, 2017, 364(5): fnx042.","DOI":"10.1093\/femsle\/fnx042"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.32","doi-asserted-by":"publisher","unstructured":"Echeverria I, Pereboev A, Silva L, et al. Enhanced T cell responses against hepatitis C virus by <i>ex vivo<\/i> targeting of adenoviral particles to dendritic cells[J]. <i>Hepatology<\/i>, 2011, 54(1): 28\u201337.","DOI":"10.1002\/hep.24325"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.33","doi-asserted-by":"publisher","unstructured":"Jirmo AC, Koya RC, Sundarasetty BS, et al. Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8<sup>+<\/sup> T cell responses[J]. <i>Vaccine<\/i>, 2010, 28(4): 922\u2013933.","DOI":"10.1016\/j.vaccine.2009.10.150"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.34","doi-asserted-by":"publisher","unstructured":"Barth H, Ulsenheimer A, Pape GR, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells[J]. <i>Blood<\/i>, 2005, 105(9): 3605\u20133614.","DOI":"10.1182\/blood-2004-05-1952"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.35","doi-asserted-by":"publisher","unstructured":"Dolganiuc A, Szabo G. Dendritic cells in hepatitis C infection: Can they (help) win the battle?[J]. <i>J Gastroenterol<\/i>, 2011, 46(4): 432\u2013447.","DOI":"10.1007\/s00535-011-0377-y"},{"key":"10.7555\/JBR.39.20250197.swyxyjzzywb.36","doi-asserted-by":"publisher","unstructured":"Tian Y, Hu D, Li Y, et al. Development of therapeutic vaccines for the treatment of diseases[J]. <i>Mol Biomed<\/i>, 2022, 3(1): 40.","DOI":"10.1186\/s43556-022-00098-9"}],"container-title":["Journal of Biomedical Research"],"original-title":[],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:20:12Z","timestamp":1774347612000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jbr-pub.org.cn\/article\/doi\/10.7555\/JBR.39.20250197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["JBR-2025-0197"],"URL":"https:\/\/doi.org\/10.7555\/jbr.39.20250197","relation":{},"ISSN":["1674-8301","1674-8301"],"issn-type":[{"value":"1674-8301","type":"print"},{"value":"1674-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}